Randomized phase III trial of a neoadjuvant regimen of four cycles of adriamycin plus cyclophosphamide followed by four cycles of docetaxel (AC4-D4) versus a shorter treatment of three cycles of FEC followed by three cycles of docetaxel (FEC3-D3) in node-positive breast cancer (Neo-shorter; NCT02001506).
Inhwan HwangJeong Eun KimJae Ho JeongJin-Hee AhnKyung Hae JungByung Ho SonHak Hee KimJunyoung ShinHee Jin LeeGyungyub GongSung-Bae KimPublished in: Breast cancer research and treatment (2023)
Six cycles of FEC3-D3 could be an alternative to eight of AC4-D4. Trial registration ClinicalTrials.gov NCT02001506. Registered December 5,2013. https://clinicaltrials.gov/ct2/show/NCT02001506.